NEW YORK (GenomeWeb News) – GeneNews on Friday reported its revenues for the second quarter dropped more than five-fold year over year.

For the three months ended June 30, the Toronto-based molecular diagnostics firm's revenues totaled C$10,019 (US$9,729), compared to C$56,304 in the second quarter of 2012, it said in a document filed with Canadian regulators.

Royalty revenues dropped to C$7,472 in the recently completed quarter from C$51,833, while sales were down to C$2,547 from C$4,471.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.